NeuroTherapeutics Pharma once again turns to SynapCell for its epilepsy drug project Press Release / November 23, 2011
The US-based developer of therapies for neurological disorders has decided to further its groundbreaking work with SynapCell to test promising new epilepsy drugs.
Grenoble, November 23, 2011 − SynapCell, an expert in assessing the efficacy of epilepsy drugs, today announces an expansion of its partnership with NeuroTherapeutics Pharma. Promising epilepsy drugs are already being tested on the MTLE mouse, a predictive model that reproduces the characteristics of an epilepsy syndrome generally refractory to treatment in humans.
Corinne Roucard, CEO of SynapCell, explained, “We recently made some significant advances that enhance drug screening. This has vastly improved our capacity to respond to NeuroTherapeutics Pharma’s preclinical drug development needs. We can now offer an effective, highly-competitive solution for drug screening on the MTLE mouse, with responses in as little as two weeks—and with unparalleled reliability and efficacy. This added value, coupled with our proven, recognized animal model for in vivo epilepsy drug trials (AED Trials XI, Miami, April 2011), has established us as a key player in the development of treatments for this pathology.”
Stephen Collins, CEO of NeuroTherapeutics Pharma, added, “Our collaboration with SynapCell is already a proven success, thanks in part to the enhanced drug screening capacity they have been able to offer us. We particularly value SynapCell’s solid expertise in this area. Their flexibility and responsiveness enable us to advance quickly, which is why we turned to them for dose-response tests for our anti-epileptic drugs in development. SynapCell is a key partner in our effort to develop new drugs for epilepsy cases that are currently difficult, or even impossible, to treat.”
SynapCell (posters 1.279 and 3.046) will be at the “American Epilepsy Society”, Baltimore, USA, on December 2-6, 2011.
SynapCell, a biotechnology company specialized in treatments for central nervous system disorders, provides the biopharmaceutical industry with innovative preclinical solutions for assessing drug efficacy and identifying possible side effects. The company couples unique scientific knowledge and neurosurgical expertise with effective predictive biological models for human diseases and powerful software for testing the electrical activity of neural networks. Learn more about SynapCell at http://www.synapcell.com.
About NeuroTherapeutics Pharma, Inc.
NeuroTherapeutics Pharma, Inc. (NTP) is a biopharmaceutical company developing new therapies to treat pain, epilepsy, and other nervous system disorders. NTP is advancing compounds that act through a novel mechanism to create a new class of medicines with potential broad application across a range of neurological and neuropsychiatric conditions. Learn more about NeuroTherapeutics Pharma at http://www.ntprx.com.